Semaglutide real-world data show 40% fewer asthma attacks in ERS study

For drug developers, the ERS data are a classic hypothesis-generating milestone: a widely prescribed asset with a plausible anti-inflammatory mechanism is linked to 40% fewer asthma attacks, yet no asthma or COPD endpoint was included in existing GLP-1 trials. The next move is a well-powered RCT to convert association into approval.

A retrospective analysis of UK electronic medical records, presented at the European Respiratory Society (ERS) International Congress in Spain in September 2026, adds to the evidence that GLP-1 receptor agonists may influence more than glucose and weight. Professor Chloe Bloom, Clinical Associate Professor in Respiratory Epidemiology, reported that people with asthma and COPD who were started on a GLP-1 medication had fewer respiratory events than comparable patients initiated on other diabetes drugs. The strongest signal was specific to semaglutide, the active ingredient in Ozempic and Wegovy: use was associated with nearly a 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups.

“

The strongest signal was specific to semaglutide, the active ingredient in Ozempic and Wegovy: use was associated with nearly a 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups.

The analysis drew on four retrospective studies using UK electronic medical records, which allowed researchers to compare outcomes in large, routine-care populations rather than tightly controlled trial cohorts. This design is important because asthma and COPD outcomes have not been included as primary or secondary endpoints in major GLP-1 drug trials. The study therefore offers an early real-world look at respiratory outcomes in patients already treated with these agents.

The biological plausibility is supported by prior work suggesting GLP-1 receptor agonists have anti-inflammatory effects and may improve lung-related outcomes. Obesity and type 2 diabetes, the two main indications for semaglutide, frequently coexist with asthma and COPD, and both conditions share metabolic and inflammatory drivers. If the association is causal, the public health payoff could be substantial: asthma attacks and COPD exacerbations drive emergency visits, hospitalizations, oral steroid exposure, disease progression, and significant healthcare costs. A 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups would be a meaningful clinical benefit on top of existing cardiometabolic effects.

For biopharmaceutical strategy, the findings point to a potential label expansion opportunity. Semaglutide is already one of the highest-grossing medicines globally, but its GLP-1 franchise faces intensifying competition from tirzepatide and emerging oral GLP-1 agents. Confirming a respiratory indication through randomized controlled trials would create new differentiation and open a large chronic disease market. However, regulators will not grant an asthma or COPD indication based on retrospective electronic health record analyses alone. A prospective trial with prespecified respiratory endpoints, adequate blinding, balanced baseline characteristics, and safety assessment would be required. The observational nature of the current study leaves room for confounding by indication, healthcare utilization patterns, smoking history, body mass index, and unmeasured variables.